spacer
home > ebr > spring 2017 > going viral
PUBLICATIONS
European Biopharmaceutical Review

Going Viral

Influenza-like illnesses have been documented as causing pandemics since Charlemagne’s army was decimated by an outbreak in 876 AD. The viruses that cause influenza make ideal agents for human challenge studies, because the ailment they induce is transient yet well characterised. The use of H1N1 or H3N2 influenza A viruses manufactured to meet rigid industry standards such as Good Manufacturing Practice (GMP) in challenge trials can effectively emulate high incidence community disease – higher indeed than pandemic infection rates (80% versus 25%), but without the risk of serious adverse events.

Influenza Strains

It has been reported that the influenza virus originally developed in bats and spread sequentially to horses, poultry and pigs before entering the human population approximately 6,000 years ago. The virus contains 18 haemagglutinin (HA) and 13 neuraminidase (NI) genes, which can reassort to generate new serotypes of influenza. Strains present in poultry show particularly rapid mutation rates. H1, H2, H3, N1 and N2 variants have evolved sustained transmission into humans, and pandemic H1N1 and H3N2 are thought to have originated towards the end of the 19th century – with the former coinciding with outbreaks in animals. Both strains have been responsible for serial pandemics since 1900.

Interestingly, while there are high case fatalities whenever a new serotype emerges, the numbers fall as exposure to it persists. For the H1N1 pandemic in 1918, the initial fatality rate was very high at 2%; however, when H1N1 re-emerged in 2009, it had dropped to just 0.03%. This is due to the virus attenuating over time, but also because the population produces antibodies and becomes resistant or even immune.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adrian Wildfire is Project Director of the Infectious Diseases and Viral Challenge Unit at SGS Life Sciences and has nearly 30 years of experience in communicable diseases. He has trained and worked within the fields of bacteriology, virology, parasitology and mycology, obtaining his Fellowship in Medical Microbiology in 1990 and a Masters in Parasitology in 1998. 
spacer
Adrian Wildfire
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

DrugDev Dominates Clinical Site Payments with Record Milestone of Over $2 Billion Processed to Sites on Behalf of Sponsors and CROs Worldwide


More info >>

White Papers

Case Study: Precision Pen Injector™

SHL Group

The Precision Pen Injector (PPI™) is an injector originally designed to deliver small yet highly precise doses of Restylane® Skinbooster™, a treatment produced by Swedish biomedical firm Q-Med AB (now Galderma) for revitalizing the skin. This innovative device received praises from doctors and clinicians alike for its ease-of-use and compact design at the 2009 IMCAS (International Master Course on Aging Skin), where the product was first officially launched. Furthermore, the PPI™ was recognized with the prestigious red dot design award for product design.
More info >>

 
Industry Events

Clinical Trial Supply Southeast Conference 2017

3-4 May 2017, Cary, North Carolina

Cary is part of the Southeast’s Research Triangle Park, a growing and thriving community of over 80 biotech and life science companies. With such a booming community, Clinical Trial Supply Southeast gives local trial sponsors and vendors the opportunity to come together and discuss the latest trials and tribulations for the local industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement